| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/04/2013 | WO2013101949A2 Composition and method for compounded therapy |
| 07/04/2013 | WO2013101929A1 Silicone-based composition for skin treatment |
| 07/04/2013 | WO2013101926A1 Benzimidazole derivatives as selective blockers of persistent sodium current |
| 07/04/2013 | WO2013101911A2 Benzimidazole derivatives as selective blockers of persistent sodium current |
| 07/04/2013 | WO2013101897A2 Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| 07/04/2013 | WO2013101830A1 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators |
| 07/04/2013 | WO2013101810A1 Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
| 07/04/2013 | WO2013101802A1 Nicotinic receptor compounds |
| 07/04/2013 | WO2013101733A1 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| 07/04/2013 | WO2013101713A1 A nutritional approach to the use of ergothioneine and vitamin d2 for hair, nail and skin growth |
| 07/04/2013 | WO2013101600A1 Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8 |
| 07/04/2013 | WO2013101598A1 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| 07/04/2013 | WO2013101552A1 Methods for treating hcv |
| 07/04/2013 | WO2013101550A1 Solid compositions comprising an hcv inhibitor |
| 07/04/2013 | WO2013101436A1 Methods of identifying and using mdm2 inhibitors |
| 07/04/2013 | WO2013101281A1 Methods and compositions for treating parkinson's disease |
| 07/04/2013 | WO2013100882A2 Combinations of diacerein and non-steroidal inflammation drugs |
| 07/04/2013 | WO2013100881A2 Combined pharmaceutical formulation containing diacerein |
| 07/04/2013 | WO2013100880A1 Formulations comprising cefuroxime |
| 07/04/2013 | WO2013100879A1 Pharmaceutical compositions comprising quetiapine |
| 07/04/2013 | WO2013100878A1 Pharmaceutical formulations comprising aripiprazole |
| 07/04/2013 | WO2013100877A1 Dexketoprofen formulations |
| 07/04/2013 | WO2013100876A1 Risperidone formulations |
| 07/04/2013 | WO2013100874A1 Effervescent pregablin formulation |
| 07/04/2013 | WO2013100873A1 Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer) |
| 07/04/2013 | WO2013100872A1 One pot process for preparing pemetrexed disodium |
| 07/04/2013 | WO2013100870A1 New antipsychotic compositions |
| 07/04/2013 | WO2013100772A1 The use of vitamin d analogues in combination with imatinib in therapy of non-small cell lung cancer |
| 07/04/2013 | WO2013100712A1 Novel blocker for vascular leakage |
| 07/04/2013 | WO2013100672A1 3,6-disubstituted indazole derivative having protein kinase inhibiting activity |
| 07/04/2013 | WO2013100632A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| 07/04/2013 | WO2013100631A1 Novel imidazopyridine derivatives as a tyrosine kinase inhibitor |
| 07/04/2013 | WO2013100630A1 Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide |
| 07/04/2013 | WO2013100571A1 Phenyl carbamate compounds for use in preventing or treating als |
| 07/04/2013 | WO2013100570A1 Phenyl carbamate compounds for use in preventing or treating epilesy |
| 07/04/2013 | WO2013100569A1 Phenyl carbamate compounds for use in preventing or treating multiple sclerosis |
| 07/04/2013 | WO2013100568A1 Phenyl carbamate compounds for use in preventing or treating stroke |
| 07/04/2013 | WO2013100567A1 Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain |
| 07/04/2013 | WO2013100566A1 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same |
| 07/04/2013 | WO2013100459A1 Composition comprising hair telogen- or catagen-inducing agent for preventing and alleviating alopecia caused by anticancer therapy |
| 07/04/2013 | WO2013100204A1 Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin |
| 07/04/2013 | WO2013098775A1 Improved process for preparation of pure linagliptin |
| 07/04/2013 | WO2013098773A1 Crystalline forms of pitavastatin calcium |
| 07/04/2013 | WO2013098764A1 Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof |
| 07/04/2013 | WO2013098763A1 Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof |
| 07/04/2013 | WO2013098675A1 Compositions for the treatment of mucous membrane diseases |
| 07/04/2013 | WO2013098588A1 Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies |
| 07/04/2013 | WO2013098578A1 Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
| 07/04/2013 | WO2013098577A1 Pharmaceutical compositions of bosentan |
| 07/04/2013 | WO2013098576A1 Immediate release pharmaceutical composition of valsartan |
| 07/04/2013 | WO2013098572A1 Complex-forming compounds |
| 07/04/2013 | WO2013098570A1 Use of estrogen derivatives for the manufacture of pharmaceutical products useful for the prophylaxis and/or treatment of psychiatric diseases |
| 07/04/2013 | WO2013098402A1 Pharmaceutical combination of fingolimod and nabiximols |
| 07/04/2013 | WO2013098381A1 Rna interference to activate stem cells |
| 07/04/2013 | WO2013098375A1 New azetidine derivatives, pharmaceutical compositions and uses thereof |
| 07/04/2013 | WO2013098374A1 1,3-diphenylpropane derivatives, preparations and uses thereof |
| 07/04/2013 | WO2013098373A1 New azetidine derivatives, pharmaceutical compositions and uses thereof |
| 07/04/2013 | WO2013098372A1 Subcutaneous therapeutic use of dpp-4 inhibitor |
| 07/04/2013 | WO2013098320A1 Quinazolinone derivatives as hcv inhibitors |
| 07/04/2013 | WO2013098313A1 Hetero-bicyclic derivatives as hcv inhibitors |
| 07/04/2013 | WO2013098264A1 Inhibitor of trpm-4 ion channel for treating or preventing neurodegeneration |
| 07/04/2013 | WO2013098145A1 Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof |
| 07/04/2013 | WO2013098140A1 Peritoneal dialysis fluid comprising a gsk-3 inhibitor |
| 07/04/2013 | WO2013098123A1 Histone deacetylase 10-inhibitor co-treatment in cancer |
| 07/04/2013 | WO2013097965A1 Triphosphate-containing double-stranded rna for immunostimulation |
| 07/04/2013 | WO2013097947A1 Pipecolate-sulfonamides for treatment of psychiatric disorders |
| 07/04/2013 | WO2013097773A1 Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators |
| 07/04/2013 | WO2013097601A1 Bromodomain inhibitors |
| 07/04/2013 | WO2013097226A1 Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors |
| 07/04/2013 | WO2013097225A1 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
| 07/04/2013 | WO2013097224A1 Fused tricyclic compounds as raf kinase inhibitors |
| 07/04/2013 | WO2013097074A1 Enhancing transdermal delivery of pde-5 inhibitor |
| 07/04/2013 | WO2013097052A1 Bromodomain inhibitors |
| 07/04/2013 | WO2013067076A3 Methods and compositions for neuroprotection |
| 07/04/2013 | WO2013064672A3 Oxazaphosphorines dosed one time for treating diseases |
| 07/04/2013 | WO2013061105A3 Glycogen phosphorylase inhibitors |
| 07/04/2013 | WO2013058627A3 Composition including rebamipide as an active ingredient for preventing or treating obesity |
| 07/04/2013 | WO2013058578A3 System for screening skin-whitening material |
| 07/04/2013 | WO2013058484A3 Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same |
| 07/04/2013 | WO2013057579A3 Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
| 07/04/2013 | WO2013057569A3 Extended release pharmaceutical composition containing amoxicillin and clavulanic acid |
| 07/04/2013 | WO2013055949A3 Pyrazol-3-ones that activate pro-apoptotic bax |
| 07/04/2013 | WO2013055385A3 Methods of treating age related disorders |
| 07/04/2013 | WO2013054364A3 Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof |
| 07/04/2013 | WO2013054345A3 Pharmaceutical combination |
| 07/04/2013 | WO2013051024A3 Quinoline-, quinoxaline or benzothiazole based cysteinyl leukotriene antagonists (ltc4) |
| 07/04/2013 | WO2013049725A3 Methods of using adenosine a1 receptor activation for treating depression |
| 07/04/2013 | WO2013049026A4 Neurabin scaffolding of the adenosine receptor and rgs4 regulates anti-seizure effect of endogenous adenosine |
| 07/04/2013 | WO2013048145A3 Composition for preventing or treating inflammatory diseases or diseases related to bone mass reduction, containing 6-(3-hydroxyphenyl)-2-naphthol or pharmaceutically acceptable salt thereof as active ingredient |
| 07/04/2013 | WO2013038195A3 Pharmaceutical nanoparticle compositions |
| 07/04/2013 | WO2013035997A3 Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt |
| 07/04/2013 | WO2013028049A3 Composition for the percutaneous administration of active compounds providing a suitable treatment for androgenetic alopecia |
| 07/04/2013 | WO2013024467A3 Mitochondrial ribosomal proteins as aging regulators |
| 07/04/2013 | WO2013019733A4 Methods, compositions and kits for therapeutic treatment with wet spun microstructures |
| 07/04/2013 | WO2013019561A8 Nuclear transport modulators and uses thereof |
| 07/04/2013 | WO2013010136A3 Inhibitors of bruton's tyrosine kinase |
| 07/04/2013 | WO2012145575A4 Therapy for leukemia |
| 07/04/2013 | WO2012054526A8 Chemosensory receptor ligand-based therapies |
| 07/04/2013 | WO2012003562A8 Antineoplastic pharmaceutical compositions containing substituted nitroimidazoles |
| 07/04/2013 | WO2008149137A3 Tegaserod benzoate and polymorphic forms |